← Back to patent-cliff list
CAS 79-22-1
methyl carbonochloridateCarbonochloridic acid methyl ester
Codes: ROSU-031, RIOC-012, PEME-028, (VI)236036-8-a, (VIII)263642-6-a, (IVb)263642-7-a, ANAC-034
Application context (from source-drug indications)
HypertensionFimasartan potassium trihydrate/Rosuvastatin calciumDyslipidaemiaFimasartan potassium trihydrate/Rosuvastatin calciumHypertensionRosuvastatin Calcium/TelmisartanHyperlipidaemiaRosuvastatin Calcium/TelmisartanPulmonary arterial hypertensionRiociguatPulmonary hypertensionRiociguatChronic thromboembolic pulmonary hypertensionRiociguatThrombosisRiociguatLeft ventricular dysfunctionRiociguatIdiopathic pulmonary arterial hypertensionRiociguatHomozygous familial hypercholesterolaemiaRosuvastatin CalciumHeterozygous familial hypercholesterolaemiaRosuvastatin CalciumHyperlipoproteinaemia type IIIRosuvastatin CalciumAtherosclerosisRosuvastatin CalciumHyperlipoproteinaemia type IIRosuvastatin CalciumHypercholesterolaemiaRosuvastatin CalciumNon-small cell lung cancerPemetrexed Disodium Hydrate间皮组织肿瘤Pemetrexed Disodium Hydrate胸膜孤立性纤维瘤Pemetrexed Disodium HydrateBladder cancerPemetrexed Disodium HydrateUrothelial carcinomaPemetrexed Disodium HydrateSolid tumourPemetrexed Disodium Hydrate分离性焦虑S-fluoxetineAnxietyS-fluoxetineAnxiety disorderS-fluoxetine分离性焦虑R-fluoxetineAnxietyR-fluoxetineAnxiety disorderR-fluoxetineHypercholesterolaemiaAnacetrapibCardiac and vascular disordersAnacetrapibDyslipidaemiaAnacetrapibAtherosclerosisAnacetrapibHyperlipoproteinaemia type IIAnacetrapibHomozygous familial hypercholesterolaemiaAnacetrapib
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Fimasartan potassium trihydrate/Rosuvastatin calcium | Tier C — Watch / trade | - |
| Rosuvastatin Calcium/Telmisartan | Tier C — Watch / trade | - |
| Riociguat | Tier B — Position early | - |
| Rosuvastatin Calcium | Tier B — Position early | - |
| Pemetrexed Disodium Hydrate | Tier B — Position early | - |
| S-fluoxetine | Tier C — Watch / trade | - |
| R-fluoxetine | Tier C — Watch / trade | - |
| Anacetrapib | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
N-(4-(4-fluorophenyl)-5-formyl-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide→sodium (3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoate→ethyl (R)-4-cyano-3-hydroxybutanoate→ethyl (R)-3-((tert-butyldimethylsilyl)oxy)-4-cyanobutanoate→(R)-3-((tert-butyldimethylsilyl)oxy)-4-cyanobutanoic acid→tert-butyl (R)-3-((tert-butyldimethylsilyl)oxy)-4-cyanobutanoate→tert-butyl (R)-5-amino-3-((tert-butyldimethylsilyl)oxy)-5-oxopentanoate→(R)-5-(tert-butoxy)-3-((tert-butyldimethylsilyl)oxy)-5-oxopentanoic acid→methyl carbonochloridate→(S)-(R)-5-(tert-butoxy)-3-((tert-butyldimethylsilyl)oxy)-5-oxopentanoic (ethyl carbonic) anhydride→methyltriphenylphosphonium bromide→tert-butyl (R)-3-((tert-butyldimethylsilyl)oxy)-5-oxo-6-(triphenyl-l5-phosphanylidene)hexanoate→tert-butyl (R,E)-3-((tert-butyldimethylsilyl)oxy)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-5-oxohept-6-enoate→tert-butyl (R,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3-hydroxy-5-oxohept-6-enoate→tert-butyl (3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoate
N-(4-(4-fluorophenyl)-5-formyl-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide→methyl carbonochloridate→methyltriphenylphosphonium bromide→4-((tert-butyldimethylsilyl)oxy)dihydro-2H-pyran-2,6(3H)-dione→(R)-1-phenylethan-1-amine→(S)-3-((tert-butyldimethylsilyl)oxy)-5-oxo-5-(((R)-1-phenylethyl)amino)pentanoic acid→(S)-3-((tert-butyldimethylsilyl)oxy)-5-oxo-5-(((R)-1-phenylethyl)amino)pentanoic (methyl carbonic) anhydride→(R)-3-((tert-butyldimethylsilyl)oxy)-5-oxo-N-((R)-1-phenylethyl)-6-(triphenyl-l5-phosphanylidene)hexanamide→(R,E)-3-((tert-butyldimethylsilyl)oxy)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-5-oxo-N-((R)-1-phenylethyl)hept-6-enamide→(R,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3-hydroxy-5-oxo-N-((R)-1-phenylethyl)hept-6-enamide→(3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxy-N-((R)-1-phenylethyl)hept-6-enamide
N-(4-(4-fluorophenyl)-5-formyl-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide→sodium (3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoate→ethyl (R)-4-cyano-3-hydroxybutanoate→ethyl (R)-3-((tert-butyldimethylsilyl)oxy)-4-cyanobutanoate→(R)-3-((tert-butyldimethylsilyl)oxy)-4-cyanobutanoic acid→tert-butyl (R)-3-((tert-butyldimethylsilyl)oxy)-4-cyanobutanoate→tert-butyl (R)-5-amino-3-((tert-butyldimethylsilyl)oxy)-5-oxopentanoate→(R)-5-(tert-butoxy)-3-((tert-butyldimethylsilyl)oxy)-5-oxopentanoic acid→methyl carbonochloridate→(S)-(R)-5-(tert-butoxy)-3-((tert-butyldimethylsilyl)oxy)-5-oxopentanoic (ethyl carbonic) anhydride→methyltriphenylphosphonium bromide→tert-butyl (R)-3-((tert-butyldimethylsilyl)oxy)-5-oxo-6-(triphenyl-l5-phosphanylidene)hexanoate→tert-butyl (R,E)-3-((tert-butyldimethylsilyl)oxy)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-5-oxohept-6-enoate→tert-butyl (R,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3-hydroxy-5-oxohept-6-enoate→tert-butyl (3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoate
N-(4-(4-fluorophenyl)-5-formyl-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide→methyl carbonochloridate→methyltriphenylphosphonium bromide→4-((tert-butyldimethylsilyl)oxy)dihydro-2H-pyran-2,6(3H)-dione→(R)-1-phenylethan-1-amine→(S)-3-((tert-butyldimethylsilyl)oxy)-5-oxo-5-(((R)-1-phenylethyl)amino)pentanoic acid→(S)-3-((tert-butyldimethylsilyl)oxy)-5-oxo-5-(((R)-1-phenylethyl)amino)pentanoic (methyl carbonic) anhydride→(R)-3-((tert-butyldimethylsilyl)oxy)-5-oxo-N-((R)-1-phenylethyl)-6-(triphenyl-l5-phosphanylidene)hexanamide→(R,E)-3-((tert-butyldimethylsilyl)oxy)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-5-oxo-N-((R)-1-phenylethyl)hept-6-enamide→(R,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3-hydroxy-5-oxo-N-((R)-1-phenylethyl)hept-6-enamide→(3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxy-N-((R)-1-phenylethyl)hept-6-enamide
(2-fluorobenzyl)hydrazine→sodium (Z)-1-cyano-3-ethoxy-3-oxoprop-1-en-2-olate→ethyl 5-amino-1-(2-fluorobenzyl)-1H-pyrazole-3-carboxylate→(E)-3-(dimethylamino)acrylaldehyde→ethyl 1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate→1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide→1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carbonitrile→1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboximidamide→(E)-2-(phenyldiazenyl)malononitrile→(E)-2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-5-(phenyldiazenyl)pyrimidine-4,6-diamine→2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidine-4,5,6-triamine→methyl carbonochloridate→methyl (4,6-diamino-2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-5-yl)carbamate
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.